RxDoctor Payments DataLook up a doctor →

Chinmay Patel, MD

Cardiovascular Disease · Lancaster, PANPI 1477666758

Payments from drug & device makers

$1,435,763in general payments, 2019–2025

Across 570 payments — averaging $2518.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1M
  • Medical Device Business Services, Inc.$271K
  • Abbott$93K
  • Medtronic$40K
  • Atricure, Inc.$2K
  • W. L. Gore & Associates, Inc.$1K
  • plus $222 from 7 others

What the payments were for

  • Consulting fees$5,06010%
  • Speaking & faculty fees$40,39479%
  • Travel & lodging$2,2414%
  • Food & beverage$3,1946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,435,763 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$262,544
Medicare patients
1,336
Services billed
4,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban450$594,271
XareltoRivaroxaban182$194,250
MultaqDronedarone Hcl67$83,630
EntrestoSacubitril/Valsartan36$51,876
Metoprolol Succinate482$11,577
Flecainide Acetate205$11,393
Dofetilide40$10,415
Diltiazem 24hr Er (Cd)Diltiazem Hcl209$7,508
DapagliflozinDapagliflozin Propanediol12$6,308
Repatha SyringeEvolocumab12$6,189
Repatha SureclickEvolocumab12$6,064
Amiodarone Hcl89$3,148
Mexiletine Hcl23$2,965
SotalolSotalol Hcl86$2,607
Ranolazine ErRanolazine28$2,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$594,271450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →